ReviewPediatric research2021
Pulmonary hypertension in bronchopulmonary dysplasia.
Review in Pediatric research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 144 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
144 citing papers in PubMed, 4 syntheses or guidelines pooled it, 229 citations in OpenAlex.
- Incidence and risk factors of pulmonary hypertension in neonates with congenital diaphragmatic hernia: a systematic review and meta-analysis.Pediatric surgery international · 2025Pooled it
- Inhaled Nitric Oxide for Bronchopulmonary Dysplasia-Associated Pulmonary Hypertension: A Systematic Review and Narrative Synthesis.Neonatology · 2025Pooled it
- The association between VEGF genetic variations and the risk of bronchopulmonary dysplasia in premature infants: a meta-analysis and systematic review.Frontiers in pediatrics · 2024Pooled it
- Patent Ductus Arteriosus and Bronchopulmonary Dysplasia-Associated Pulmonary Hypertension: A Bayesian Meta-Analysis.JAMA network open · 2023Pooled it
- Multi-dose enteral L-citrulline administration in premature infants at risk of developing pulmonary hypertension associated with bronchopulmonary dysplasia.Journal of perinatology : official journal of the California Perinatal Association · 2024Trial
- Oral versus intravenous sildenafil for pulmonary hypertension in neonates: a randomized trial.BMC pediatrics · 2022Trial
- Macitentan attenuates cardiovascular remodelling in infant rats with chronic lung disease.Journal of translational medicine · 2022Trial
- Lung Ultrasound in Bronchopulmonary Dysplasia: Diagnostic Tool, Prognostic Marker or Monitoring Strategy?Children (Basel, Switzerland) · 2026Review
- The autonomic nervous system-lung interface in experimental BPD: NPY modulates immune response, alveolar growth and vascular muscularizationin neonatal mice exposed to oxidative stress.Respiratory research · 2026Article
- Factors associated with short-term response after systemic corticosteroid treatment in invasively ventilated preterm infants.BMC pediatrics · 2026Article
- L-Citrulline: Novel Pharmacotherapy to Improve Outcomes in Infants and Children at Risk of Systemic or Pulmonary Vascular Disease.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Endothelial SP1 lactylation promotes bronchopulmonary dysplasia via regulation of Cdkn1a expression.Scientific reports · 2026Article
- Bronchopulmonary dysplasia associated pulmonary hypertension: implications across the lifespan.Paediatric respiratory reviews · 2026Review
- Tissue Doppler Imaging, Pulmonary Haemodynamics and Conventional Echocardiographic Indices for Early Bronchopulmonary Dysplasia Prediction in Preterm Infants: A Prospective Observational Feasibility Study.Children (Basel, Switzerland) · 2026Article
- Effects of Continuous Low-dose Nitric Oxide in a Murine Model of Pulmonary Hypertension with Impaired Lung Development.Anesthesiology · 2026Article
- Refractory Lung Diseases: From Cellular Structures, Molecular Mechanisms to Therapeutic Strategies.Pediatric discovery · 2026Review
- Screening for pulmonary hypertension in preterm infants with bronchopulmonary dysplasia: when, how often and does it matter?Archives of disease in childhood. Fetal and neonatal edition · 2026Article
- Predicting pulmonary hypertension in infants with bronchopulmonary dysplasia.Journal of perinatology : official journal of the California Perinatal Association · 2026Article
- Physiology-Based Diagnosis and Management of Bronchopulmonary Dysplasia Associated Pulmonary Hypertension (BPD-PH).Children (Basel, Switzerland) · 2026Review
- Variable clinical and hemodynamic effect of sildenafil in extreme premature infants with bronchopulmonary dysplasia-associated pulmonary hypertension.Journal of perinatology : official journal of the California Perinatal Association · 2026Article
84 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 6 institutions in 4 countries.
Funding
Abstract
Bronchopulmonary dysplasia (BPD) is a major complication in prematurely born infants. Pulmonary hypertension (PH) associated with BPD (BPD-PH) is characterized by alveolar diffusion impairment, abnormal vascular remodeling, and rarefication of pulmonary vessels (vascular growth arrest), which lead to increased pulmonary vascular resistance and right heart failure. About 25% of infants with moderate to severe BPD develop BPD-PH that is associated with high morbidity and mortality. The recent evolution of broader PH-targeted pharmacotherapy in adults has opened up new treatment options for infants with BPD-PH. Sildenafil became the mainstay of contemporary BPD-PH therapy. Additional medications, such as endothelin receptor antagonists and prostacyclin analogs/mimetics, are increasingly being investigated in infants with PH. However, pediatric data from prospective or randomized controlled trials are still sparse. We discuss comprehensive diagnostic and therapeutic strategies for BPD-PH and briefly review the relevant differential diagnoses of parenchymal and interstitial developmental lung diseases. In addition, we provide a practical framework for the management of children with BPD-PH, incorporating the modified definition and classification of pediatric PH from the 2018 World Symposium on Pulmonary Hypertension, and the 2019 EPPVDN consensus recommendations on established and newly developed therapeutic strategies. Finally, current gaps of knowledge and future research directions are discussed. IMPACT: PH in BPD substantially increases mortality. Treatment of BPD-PH should be conducted by an interdisciplinary team and follow our new treatment algorithm while still kept tailored to the individual patient. We discuss recent developments in BPD-PH, make recommendations on diagnosis, monitoring and treatment of PH in BPD, and address current gaps of knowledge and potential research directions. We provide a practical framework, including a new treatment algorithm, for the management of children with BPD-PH, incorporating the modified definition and classification of pediatric PH (2018 WSPH) and the 2019 EPPVDN consensus recommendations on established and newly developed therapeutic strategies for BPD-PH.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.